Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 13/20 | 0.50 |
| ▸ | HTR7 | P34969 | 3/20 | 0.49 |
| ▸ | HDAC3 | O15379 | 3/20 | 0.45 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.45 |
| ▸ | HDAC2 | Q92769 | 3/20 | 0.45 |
| ▸ | HDAC6 | Q9UBN7 | 3/20 | 0.45 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.43 |
| ▸ | HTR2C | P28335 | 1/20 | 0.43 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.43 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.43 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6081327 | 0.91 | MAPK14 (0.52) | MAPK14HTR7HDAC3HDAC1HDAC2 | |
| SCHEMBL6081738 | 0.90 | MAPK14 (0.49) | MAPK14HTR7HDAC3HDAC1HDAC2 | |
| SCHEMBL6081490 | 0.88 | MAPK14 (0.50) | MAPK14HTR7HDAC3HDAC1HDAC2 | |
| SCHEMBL6081874 | 0.88 | MAPK14 (0.47) | MAPK14HTR7HDAC3HDAC1HDAC2 | |
| SCHEMBL6081688 | 0.81 | MAPK14 (0.44) | MAPK14HTR7HDAC3HDAC1HDAC2 | |
| SCHEMBL20187393 | 0.81 | MAPK14 (0.56) | MAPK14HTR7HDAC3HDAC1HDAC2 | |
| SCHEMBL30123472 | 0.81 | MAPK14 (0.56) | MAPK14HTR7HDAC3HDAC1HDAC2 | |
| SCHEMBL6082153 | 0.79 | MAPK14 (0.54) | MAPK14HTR7HDAC3HDAC1HDAC2 | |
| SCHEMBL6081184 | 0.78 | MAPK14 (0.45) | MAPK14HTR7HDAC3HDAC1HDAC2 | |
| SCHEMBL20209435 | 0.78 | MAPK14 (0.53) | MAPK14HTR7HDAC3HDAC1HDAC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060199821-A1 | Heterocyclic amides and sulfonamides | SCIOS, INC. (US) | 2006-09-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060199821-A1 | Heterocyclic amides and sulfonamides | MAP4K2, MAP3K8, MAP3K2 | MAPK14 28/4885HTR7 1715/4885HDAC3 181/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.